Chembio Diagnostics, Inc. (NASDAQ:CEMI) – Stock analysts at Zacks Investment Research increased their FY2018 EPS estimates for Chembio Diagnostics in a note issued to investors on Wednesday. Zacks Investment Research analyst B. Marckx now forecasts that the company will post earnings per share of ($0.23) for the year, up from their previous estimate of ($0.27). Zacks Investment Research also issued estimates for Chembio Diagnostics’ FY2019 earnings at ($0.11) EPS.

Shares of Chembio Diagnostics (NASDAQ:CEMI) traded down $0.13 on Monday, hitting $7.15. 10,700 shares of the stock traded hands, compared to its average volume of 21,171. Chembio Diagnostics has a 52 week low of $5.05 and a 52 week high of $7.60. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.54 and a quick ratio of 2.19.

Several institutional investors and hedge funds have recently made changes to their positions in CEMI. Royce & Associates LP acquired a new position in shares of Chembio Diagnostics during the second quarter valued at $132,000. Goldman Sachs Group Inc. acquired a new position in shares of Chembio Diagnostics during the second quarter valued at $151,000. Benchmark Capital Advisors boosted its holdings in shares of Chembio Diagnostics by 174.2% during the third quarter. Benchmark Capital Advisors now owns 32,900 shares of the company’s stock valued at $204,000 after acquiring an additional 20,900 shares during the period. Wells Fargo & Company MN boosted its holdings in shares of Chembio Diagnostics by 55.4% during the second quarter. Wells Fargo & Company MN now owns 74,186 shares of the company’s stock valued at $449,000 after acquiring an additional 26,436 shares during the period. Finally, ARS Investment Partners LLC boosted its holdings in shares of Chembio Diagnostics by 29.4% during the second quarter. ARS Investment Partners LLC now owns 671,681 shares of the company’s stock valued at $4,064,000 after acquiring an additional 152,686 shares during the period. 34.07% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://www.watchlistnews.com/zacks-investment-research-weighs-in-on-chembio-diagnostics-inc-s-fy2018-earnings-cemi/1757512.html.

Chembio Diagnostics Company Profile

Chembio Diagnostics, Inc (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc, develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company’s products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies.

Earnings History and Estimates for Chembio Diagnostics (NASDAQ:CEMI)

Receive News & Ratings for Chembio Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chembio Diagnostics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.